Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBV87 Chikungunya Vaccine Phase II/III in Healthy Subjects
NCT04566484Phase 3Terminated
- Sponsor
- International Vaccine Institute
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of BBV87 in Chikungunya (CHIKV) (4 arms), sponsored by International Vaccine Institute. Primary endpoints: Geometric Mean Titers of Neutralization Antibody and Treatment Emergent Adverse Events. Started Aug 2021; status: terminated.
02
Drugs
BBV87
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT04566484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566484.